News | June 08, 2022
Merck and Ridgeback announce new data for investigational molnupiravir
Based on a post hoc analysis, fewer required respiratory interventions
Based on a post hoc analysis, fewer required respiratory interventions
Merck has shared these additional analyses with the FDA and they will be presented to the FDA’s Antimicrobial Drugs Advisory Committee on Nov. 30th
If authorized, molnupiravir could be the first oral antiviral medicine for the treatment of Covid-19
If cleared, Merck's drug would be the first pill shown to treat Covid-19, a potentially major advance in efforts to fight the pandemic
Merck and Ridgeback will appeal the decision and request a re-examination of the CHMP’s opinion.
Among patients with infectious virus at baseline, no patients who received Lagevrio had infectious virus at days 3, 5 or 10
The drug is to be supplied in 105 low and middle-income countries and 10 Indian firms are on the list
This agreement allows Natco to expand access to Covid-19 medicines in 105 countries in generic name
A toll-free helpline to be set up to help doctors and patients
The product is expected to be available in a week’s time
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)